Paired Conversations: The Management of Patients With Hepatorenal Syndrome-Acute Kidney Injury: An International Perspective

To participate in this activity, please:

Hepatorenal syndrome (HRS) represents an acute complication of decompensated cirrhosis and is a subtype of acute kidney injury (AKI), with high associated mortality. This activity consists of 6 paired conversations with experts from Europe and the United States in the fields of hepatology, critical care, nephrology, and transplantation. During these paired conversations, the faculty explore revised diagnostic criteria, emerging treatment, and coordinating effective multidisciplinary care. In addition, the faculty panel collaboratively reviews a patient case where they share international perspectives on the nonpharmacological and pharmacological treatment of patients with HRS-AKI.

This program is also available as a podcast. You may download it here:

Course Credit:

1.75 ACPE Contact Hours
1.75 AMA PRA Category 1 CreditsTM
1.75 ANCC Contact Hours


Opens: 2022-08-15
Closes: 2023-08-15

Target Audience:

This activity is intended for a national audience of critical care physicians, hepatologists, nephrologists, transplant surgeons, critical care pharmacists, nurse practitioners, physician assistants, and other clinicians who care for patients with hepatorenal syndrome-acute kidney injury (HRS-AKI).

This activity is supported by an educational grant from Mallinckrodt.


In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1.75 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.75 contact hours.

Additional Content Planners

Ishaq Lat, PharmD (Medical Writer)
No significant relationships to disclose.

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Paolo Angeli, MD, PhD

    Unit of Hepatic Emergencies and Liver Transplantation
    University of Padova
    Padova, Italy

  • Amanda Chaney, DNP, APRN

    Senior Director of Advanced Practice Services
    Cleveland Clinic
    Florida Region
    Weston, Florida

  • Kevin Moore, MB.BS, PhD

    Institute of Liver and Digestive Health
    University College
    London, United Kingdom

  • Mitra K. Nadim, MD

    Director, USC Hypertension Center
    Keck Medicine of USC
    Los Angeles, California

  • Rahul Nanchal, MD

    Division of Pulmonary and Critical Care Medicine
    Medical College of Wisconsin
    Milwaukee, Wisconsin

  • Ram Subramanian, MD, MBA

    Director of Liver Critical Care Services
    Emory University School of Medicine
    Atlanta, Georgia

Learning Objectives

  • Implement American Association for the Study of Liver Disease (AASLD) criteria in the diagnosis of patients with HRS-AKI
  • Discuss the role of nonpharmacologic and pharmacologic therapies for the treatment of HRS-AKI according to current AASLD and Society of Critical Care Medicine (SCCM) guideline recommendations
  • Compare the clinical pharmacology of currently available and emerging vasoconstrictors for HRS-AKI
  • Describe the safety and efficacy of vasoconstrictor options for the treatment of patients with HRS-AKI, based on clinical trials and real-world, international experience
  • Compare treatment approaches to HRS-AKI recommended in AASLD and SCCM guidelines
  • Apply current guideline recommendations as a multidisciplinary care team in treating patients with HRS-AKI

Faculty Disclosures

Paolo Angeli, MD, PhD

Advisory Board: BioVie, Gilead, Ferring

Research Support: Gilead

Speakers Bureau: CSL Behring, Grifols, Kedrion

Amanda Chaney, DNP, APRN

Author: Springer Publishing

Kevin Moore, MB.BS, PhD

Consultant: Mallinckrodt Pharmaceuticals

Mitra K. Nadim, MD

Consultant: Mallinckrodt Pharmaceuticals

Rahul Nanchal, MD

No relationships to disclose.

Ram Subramanian, MD, MBA

Consultant: Mallinckrodt Pharmaceuticals